Home - Organovo, Inc.
Organovo Announces Close of the Sale of FXR Program to Eli Lilly and Company Read More »
Who We Are - Organovo, Inc.
Organovo creates human models of inflammatory bowel disease (IBD) using our 3D tissue technologies and uses them to understand, invent, and develop the best drug therapies for …
Pipeline - Organovo, Inc.
Organovo expects FXR314 to have a widening set of therapeutic applications as we advance our knowledge and our science. In addition to FXR314, Organovo is planning to begin medicinal …
About - Organovo, Inc.
© 2025 Organovo Holdings Inc. 11555 Sorrento Valley Road, Suite 100 San Diego, CA 92121
Organovo Announces FXR Program
Mar 21, 2023 · Organovo’s FXR program announcement updates its previous guidance that it would first begin Phase 1 trials in 2025. The Company plans to give guidance on Phase 2 …
News & Events - Organovo, Inc.
Organovo Provides Update on Cash and Nasdaq Continued Listing Requirements. Mar 27, 2025. Organovo Provides Business Update. Recent Media. May 6, 2019. Organovo: Bioprinting …
3D bioprinted therapeutic liver tissue - Organovo, Inc.
The critical shortage of donor organs creates an urgent need for novel treatments for patients with inborn errors of metabolism and end stage liver failure. Conventional cell therapy and tissue …
%PDF-1.7 % 10 0 obj /Filter /FlateDecode /Length 8517 >> stream xœí]ÛŽäÈq}Ÿ¯¨g æ2ï™Àb îžiÁ lk=/Ö’ cV å Ïw²ŠU•,ò qȬêšîÒj¥ ² ...
Board of Directors - Organovo, Inc.
Ms. Joshi is an experienced speaker, panelist, and presenter at several biomedical conferences both in the U.S and internationally. Ms. Joshi has co-authored several published peer …
Press Releases - Organovo Holdings, Inc.
Apr 2, 2025 · Organovo’s FXR Program, including FXR314, to Be Acquired by Eli Lilly and Company